Regeneron Pharmaceuticals
REGN
1,273 hedge funds and large institutions have $80.8B invested in Regeneron Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 185 funds opening new positions, 444 increasing their positions, 441 reducing their positions, and 68 closing their positions.
172% more first-time investments, than exits
New positions opened: 185 | Existing positions closed: 68
8% more funds holding
Funds holding: 1,177 → 1,273 (+96)
8% more capital invested
Capital invested by funds: $75.1B → $80.8B (+$5.67B)
1% more repeat investments, than reductions
Existing positions increased: 444 | Existing positions reduced: 441
0.36% more ownership
Funds ownership: 85.45% → 85.81% (+0.36%)
14% less funds holding in top 10
Funds holding in top 10: 29 → 25 (-4)
35% less call options, than puts
Call options by funds: $1.25B | Put options by funds: $1.93B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$392M |
| 2 |
Millennium Management
New York
|
+$200M |
| 3 |
Amundi
Paris,
France
|
+$188M |
| 4 |
Neuberger Berman Group
New York
|
+$184M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$181M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.23B |
| 2 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
-$345M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$333M |
| 4 |
BlackRock
New York
|
-$202M |
| 5 |
Two Sigma Advisers
New York
|
-$189M |
REGN Hedge Fund Activity: Q4 2023 in Review
1,273 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2023, worth a combined $80.8B — up 7.5% from $75.1B a quarter earlier.
Buyers outnumbered sellers: 185 funds opened new REGN positions and 68 closed out — a net gain of 117 holders — while 444 added to existing stakes and 441 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $392M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.23B.
- 1,273 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2023, up from 1,177 in Q3 2023.
- Funds reported $80.8B of Regeneron Pharmaceuticals stock for Q4 2023, up 7.5% quarter-over-quarter.
- 185 funds opened new Regeneron Pharmaceuticals positions in Q4 2023 and 68 closed out, a net change of +117 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2023 was Fidelity Investments, an estimated $392M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2023 was T. Rowe Price Associates, an estimated $1.23B sold.
Based on aggregated 13F filings for Q4 2023.